47|1124|Public
50|$|The VHL (<b>Von</b> <b>Hippel-Lindau)</b> <b>gene</b> encodes a {{component}} of an E3 Ubiquitin Ligase. VHL complex targets member of the hypoxia-inducible transcription factor family (HIF) for degradation by interacting with the oxygen-dependent destruction domain under normoxic condition. HIF activates downstream targets such as the vascular endothelial growth factor (VEGF), promoting angiogenesis. Mutations in VHL prevent degradation of HIF and thus lead {{to the formation of}} hypervascular lesions and renal tumors.|$|E
50|$|Chuvash polycythemia: An {{autosomal}} recessive form of erythrocytosis which is endemic in patients from Chuvashia, an autonomous republic within the Russian Federation. Chuvash polycythemia {{is associated with}} homozygosity for a C598T mutation in the <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> (VHL), which is needed {{for the destruction of}} HIF in the presence of oxygen. Clusters of patients with Chuvash polycythemia have been found in other populations, such as on the Italian island of Ischia, located in the Bay of Naples.|$|E
50|$|HIF1A {{overexpression}} in tumors {{may also}} {{occur in a}} hypoxia-independent pathway. In hemagioblastoma, HIF1A expression is found in most cells sampled from the well-vascularized tumor. Although in both renal carcinoma and hemagioblastoma, the <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> is inactivated, HIF1A is still expressed at high levels. In addition to VEGF overexpression in response elevated HIF1A levels, the PI3K/AKT pathway is also involved in tumor growth. In prostate cancers, the commonly occurring PTEN mutation is associated with tumor progression toward aggressive stage, increased vascular density and angiogenesis.|$|E
5000|$|Inactivation of <b>von</b> <b>Hippel-Lindau</b> disease (VHL) <b>gene</b> by gene {{mutation}} and promoter hypermethylation ...|$|R
50|$|<b>Von</b> <b>Hippel-Lindau</b> disease (VHL) is {{a disease}} which results from a {{mutation}} in the <b>von</b> <b>Hippel-Lindau</b> tumor suppressor <b>gene</b> on chromosome 3p25.3.|$|R
40|$|We {{investigated}} whether {{smoking is}} associated with mutations in the <b>Von</b> <b>Hippel-Lindau</b> (VHL) <b>gene</b> in 337 cases of sporadic renal cell carcinoma (RCC) among 120 852 people followed for 11. 3 years; {{the findings suggest that}} smoking causes RCC independently of VHL gene mutations. © 2006 Cancer Research. Chemicals / CAS: adenine, 22177 - 51 - 1, 2922 - 28 - 3, 73 - 24 - 5; cytosine, 71 - 30 - 7; guanine, 69257 - 39 - 2, 73 - 40 - 5; thymine, 65 - 71 - 4; <b>Von</b> <b>Hippel-Lindau</b> Tumor Suppressor Protein, EC 6. 3. 2. 1...|$|R
40|$|Inheritance of a mutant allele of the von Hippel-Lindau tumor {{suppressor}} gene predisposes affected individuals to develop renal cysts and clear cell renal cell carcinoma. <b>Von</b> <b>Hippel-Lindau</b> <b>gene</b> inactivation in single renal tubular cells has indirectly been showed by immunohistochemical staining for the hypoxia-inducible factor alpha target gene product carbonic anhydrase IX. In this study {{we were able to}} show <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> deletion in carbonic anhydrase IX positive nonneoplastic renal tubular cells, in epithelial cells lining renal cysts and in a clear cell renal cell carcinoma of a von Hippel-Lindau patient. This was carried out by means of laser confocal microscopy and immunohistochemistry in combination with fluorescence in situ hybridization. Carbonic anhydrase IX negative normal renal tubular cells carried no <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> deletion. Furthermore, recent studies have indicated that the <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> product is necessary for the maintenance of primary cilia stability in renal epithelial cells and that disruption of the cilia structure by <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> inactivation induces renal cyst formation. In our study, we show a significant shortening of primary cilia in epithelial cells lining renal cysts, whereas, single tubular cells with a <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> deletion display to a far lesser extent signs of cilia shortening. Our in vivo results support a model in which renal cysts represent precursor lesions for clear cell renal cell carcinoma and arise from single renal tubular epithelial cells owing to <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> deletion...|$|E
40|$|CD 70 {{upregulation}} by hypoxia-inducible {{factor and}} CD 27 (+) lymphocyte tumor infiltration {{are associated with}} worse survival in <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> (VHL) mutated clear cell renal cell carcinoma (ccRCC). CD 70 /CD 27 interaction is accompanied by high soluble CD 27 levels in the sera of ccRCC patients suggesting that soluble CD 27 is a potential predictive tool for anti-CD 70 therapy...|$|E
40|$|Many {{adaptive}} {{responses to}} hypoxia involve changes in gene transcription {{mediated by the}} hypoxia-inducible factor 1 complex. Central to this is oxygen-dependent proteolysis of the alpha subunit, which has recently been shown to require the von Hippel-Lindau tumour-suppressor protein. This observation provides one mechanism by which inherited defects in the <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> could cause features of the clinical syndrome, and offers insight into the events leading to sporadic clear cell renal cancer. Furthermore, it clearly implicates the von Hippel-Lindau tumour-suppressor protein in the biochemistry of oxygen sensing...|$|E
50|$|<b>Von</b> <b>Hippel-Lindau</b> (VHL) {{disease is}} a rare, {{autosomal}} dominant genetic condition that predisposes individuals to benign and malignant tumors. The most common tumors in VHL are central nervous system and retinal hemangioblastomas, clear cell renal carcinomas, pheochromocytomas, pancreatic neuroendocrine tumours, pancreatic cysts, endolymphatic sac tumors and epididymal papillary cystadenomas. VHL results from a mutation in the <b>von</b> <b>Hippel-Lindau</b> tumor suppressor <b>gene</b> on chromosome 3p25.3.|$|R
40|$|A {{patient with}} {{germline}} <b>von</b> <b>Hippel-Lindau</b> (VHL) <b>gene</b> alteration {{and history of}} multiple tumors present with classical paraneoplastic syndrome (PNS) associated with renal cell carcinoma (RCC). She underwent open nephron sparing surgery with resolution of symptoms. She remained without recurrence of RCC for the initial 2  years of her follow-up. To {{the best of our}} knowledge, this case represents the first in which PNS was specifically resolved using a partial nephrectomy in a patient with VHL. This case report provides initial evidence for the potential role of nephron sparing surgery in the management of paraneoplastic symptoms associated with hereditary RCC...|$|R
50|$|<b>Von</b> <b>Hippel-Lindau</b> {{disease is}} a dominantly {{inherited}} cancer syndrome that massively {{increases the risk of}} various tumors including benign hemangioblastomas and malignant pheochromocytomas, renal cell carcinomas, pancreatic endocrine tumors and endolymphatic sac tumors. It is caused by genetic mutations in the <b>Von</b> <b>Hippel-Lindau</b> tumor suppressor <b>gene.</b> The VHL protein (pVHL) is involved in cellular signalling in oxygen starved (hypoxic) cells. One role of pVHL is to cause the cellular degradation of another protein, HIF1α. Dysfunctional pVHL leads to accumulation of HIF1α, which in turn activates the production of several genes involved in cell growth and blood vessel production (VEGF, PDGFβ, TGFα and erythropoietin).|$|R
40|$|Aberrant DNA methylation, in {{particular}} promoter hypermethylation and transcriptional silencing of tumor suppressor genes, {{has an important}} role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> (VHL), the mutation frequency rates of known tumor suppressor genes in RCC are generally low, but the number of genes found to show frequent inactivation by promoter methylation in RCC continues to grow. Here, we review the genes identified as epigenetically silenced in RCC and their relationship to pathways of tumor development. Increased understanding of RCC epigenetics provides new insights into the molecular pathogenesis of RCC and opportunities for developing novel strategies for the diagnosis, prognosis and management of RCC...|$|E
40|$|Lung {{cancer is}} one of the {{malignant}} tumors with fastest growing rates in incidence and mortality in our country, also with largest threat to human health and life. However, the exact mechanisms underlying lung cancer development remain unclear. The microenvironment of tumor hypoxia was discovered in 1955, but hypoxia in lung cancer tissues had not been successfully detected till 2006. Further studies show that hypoxia not only functions through the resistance to radiotherapy, but also regulates lung cancer development, invasion, metastasis, chemotherapy resistance and prognosis through an important oncogene HIF (hypoxia inducible factor), with its regulators PHD (prolyl hydroxylase domain) and pVHL (product of <b>von</b> <b>Hippel-Lindau</b> <b>gene).</b> Therefore, hypoxia, HIF, PHD and pVHL should be considered as potential therapeutic targets for lung cancer pathogenesis and progression...|$|E
40|$|The {{product of}} the <b>von</b> <b>Hippel–Lindau</b> <b>gene,</b> pVHL, targets the α {{subunits}} of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for polyubiquitination {{in the presence of}} oxygen. The binding of pVHL to HIF is governed by the enzymatic hydroxylation of conserved prolyl residues within peptidic motifs present in the HIFα family members. By using a biochemical purification strategy, we have identified a human homolog of Caenorhabditis elegans Egl 9 as a HIF prolyl hydroxylase. In addition, we studied the activity of a structurally diverse collection of low molecular weight inhibitors of procollagen prolyl 4 -hydroxylase as potential inhibitors of the HIF hydroxylase. A model compound of this series stabilized HIF in a variety of cells, leading to the increased production of its downstream target, vascular endothelial growth factor...|$|E
40|$|One-third of top-selling {{drugs are}} derived from natu-ral products. When only a {{fraction}} of the bioactive natural products diversity has been explored, huge opportunities still remain for discovering novel leads for the development of new drugs. Clear cell renal cell carcinoma (ccRCC) is a highly vascular tumour arising from epithelial elements. Mutations in the <b>Von</b> <b>Hippel-Lindau</b> (VHL) <b>gene</b> are responsible for VHL disease and arise in the majority of Renal Cell Carcinoma (RCC) as well as in other types of cancer. Renal carcinoma cell lines with naturally occurring VHL mutations (RCC 4 VA) and their genetically matched wild-type VHL (RCC 4 VHL) counterparts were seeded onto 96 -well plates and allowed to attac...|$|R
40|$|License, which permits {{unrestricted}} use, distribution, {{and reproduction}} in anymedium, provided the originalwork is properly cited. Paragangliomas are rare neuroendocrine tumors {{that arise in}} the sympathetic or parasympathetic nervous system. Sympathetic paragangliomas are mainly found in the adrenal medulla (designated pheochromocytomas) but may also have a thoracic, abdominal, or pelvic localization. Parasympathetic paragangliomas are generally located at the head or neck. Knowledge concerning the familial forms of paragangliomas has greatly improved in recent years. Additionally to the genes involved in the classical syndromic forms: VHL <b>gene</b> (<b>von</b> <b>Hippel-Lindau),</b> RET <b>gene</b> (Multiple Endocrine Neoplasia type 2), and NF 1 gene (Neurofibromatosis type 1), 10 novel genes have so far been implicated in the occurrence of paragangliomas/pheochromocytomas...|$|R
40|$|AbstractMutations in the <b>von</b> <b>Hippel-Lindau</b> (VHL) <b>gene</b> are {{associated}} with hereditary and sporadic clear cell renal carcinoma. VHL acts in a ubiquitin ligase complex regulating hypoxia-inducible factor- 1 (HIF- 1), but the link between this function and cancer development is unclear. Here we show that in the kidneys of patients with VHL disease, HIF activation is an early event occurring in morphologically normal single cells within the renal tubules. In comparison, dysplastic lesions, cystic lesions, and tumors showed evidence of additional mechanisms that amplify HIF activation. Detection of cells with constitutive HIF activation identified {{a large number of}} previously unrecognized foci of VHL inactivation. In proximal tubules these were almost entirely unicellular, whereas multicellular foci were almost exclusively seen in the distal nephron...|$|R
40|$|The {{majority}} of kidney cancers {{are associated with}} mutations in the <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> and a small proportion are associated with infrequent mutations in other well characterized tumour-suppressor genes. In the past 15 years, efforts to uncover other key genes involved in renal cancer have identified many genes that are dysregulated or silenced via epigenetic mechanisms, mainly through methylation of promoter CpG islands or dysregulation of specific microRNAs. In addition, the advent of next-generation sequencing {{has led to the}} identification of several novel genes that are mutated in renal cancer, such as PBRM 1, BAP 1 and SETD 2, which are all involved in histone modification and nucleosome and chromatin remodelling. In this Review, we discuss how altered DNA methylation, microRNA dysregulation and mutations in histone-modifying enzymes disrupt cellular pathways in renal cancers...|$|E
40|$|Renal cell {{carcinoma}} (RCC) {{is a highly}} vascularized tumor type, which {{is often associated with}} inactivated mutations in the <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> that drives proangiogenic signaling pathways. As such, new therapies for the treatment of RCC have largely been focused on blocking angiogenesis. Sunitinib, an antiangiogenic tyrosine kinase inhibitor, is the most frequently used first-line drug for the treatment of RCC. Although treatment with sunitinib improves patient outcome considerably, acquired resistance will emerge in all cases. The molecular mechanisms of resistance to sunitinib are poorly understood, but in the past decade, several of these have been proposed. Lysosomal sequestration of sunitinib was reported as a potential resistance mechanism to sunitinib. In this review, the underlying molecular mechanisms of lysosomal sunitinib sequestration and the potential strategies to overcome this resistance are discussed to be able to further improve the treatment of RCC. </p...|$|E
40|$|PURPOSE: CD 70, {{a member}} of the TNF ligand superfamily, has been shown {{frequently}} overexpressed in clear cell renal cell carcinoma (ccRCC). The mechanisms of CD 70 's upregulation and its role in ccRCC are unknown. EXPERIMENTAL DESIGN: CD 70 expression was immunohistochemically analyzed in 667 RCCs and RCC metastases. <b>Von</b> <b>Hippel-Lindau</b> <b>gene</b> (VHL) mutations, expression patterns of VHL protein (pVHL), hypoxia-inducible factor (HIF) α, and several HIF targets were studied in tissues and cell lines and correlated with CD 70 overexpression. Gene promoter analysis was performed to confirm CD 70 as HIF target gene. Consecutive tissue sections were immunostained to reveal the relation between CD 70 -expressing RCCs and tumor-infiltrating lymphocytes positive for the CD 70 receptor (CD 27). CD 70 -mediated release of soluble CD 27 in RCC was assessed by coculture experiments and sera analysis of patients with RCC. RESULTS: Elevated CD 70 expression was seen in 80...|$|E
40|$|Renal cell {{carcinoma}} (RCC) represents the most com-mon malignancy arising {{in the adult}} kidney, with in-creasing incidence and poor prognosis [1]. RCC can be pathologically subdivided into different histological sub-types [2] based on the microscopic phenotype and {{the presence or absence}} of <b>von</b> <b>Hippel-Lindau</b> (VHL) <b>gene</b> alterations. The most frequent histological subtype is clear cell RCC (ccRCC), followed by papillary RCC (pRCC) and chromophobe RCC (chRCC). Important prognostic parameters for RCC involve tumor and nodal stage [3]. In the search of critical genes, molecular studies iden-tified several onco- and tumorsupressor gene candidates that are mutated and/or located within frequently gained and lost chromosomal regions of RCC [4 - 9]. Although multiple genes and signaling pathways have been impli-cated in renal cancer, VHL is the best characterize...|$|R
40|$|Mutations in the <b>von</b> <b>Hippel-Lindau</b> (VHL) <b>gene</b> are {{associated}} with hereditary and sporadic clear cell renal carcinoma. VHL acts in a ubiquitin ligase complex regulating hypoxia-inducible factor- 1 (HIF- 1), but the link between this function and cancer development is unclear. Here we show that in the kidneys of patients with VHL disease, HIF activation is an early event occurring in morphologically normal single cells within the renal tubules. In comparison, dysplastic lesions, cystic lesions, and tumors showed evidence of additional mechanisms that amplify HIF activation. Detection of cells with constitutive HIF activation identified {{a large number of}} previously unrecognized foci of VHL inactivation. In proximal tubules these were almost entirely unicellular, whereas multicellular foci were almost exclusively seen in the distal nephron...|$|R
40|$|We {{report a}} very rare case of hemangioblastomatosis that {{developed}} after surgical removal of a solitary cerebellar hemangioblastoma (HB). A 51 -yr-old man presented with back pain 10 yr after undergoing surgery for cerebellar HB. Magnetic resonance imaging showed numerous mass lesions along the entire neuraxis accompanied by prominent leptomeningeal enhancement. Genomic DNA analysis showed no mutation in the <b>von</b> <b>Hippel-Lindau</b> (VHL) <b>genes.</b> A surgical specimen obtained from a lesion in the cauda equina showed pathological findings identical {{to those of the}} cerebellar HB that had been resected 10 yr earlier. External beam radiation therapy and radiosurgery were subsequently performed; however, the patient succumbed one year after receiving the diagnosis of hemangioblastomatosis. The reduction of tumor cell spillage during surgery and regular long-term follow-up are recommended for patients with HBs...|$|R
40|$|Context Von Hippel-Lindau {{disease is}} an {{inherited}} syndrome of multiorgan neoplasia {{caused by a}} germline mutation in the <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> and can include central nervous system tumors, renal cell carcinomas and benign pancreatic cystic tumors. Case report We report {{the case of a}} 56 -year-old patient who had a past history of cerebellar hemangioblastoma and presented with abdominal pain. Imaging revealed renal tumors and multiple pancreatic tumors which caused duodenal and pancreatic duct compression. The patient was treated with a combination of radical right nephrectomy, total pancreaticoduodenectomy and splenectomy. Pathology identified a multifocal unilateral clear cell renal carcinoma which interestingly coexisted with multiple large pancreatic serous microcystic adenomas with infiltration of the fibrous capsule. Conclusion In past cases of von Hippel-Lindau disease, pancreatic adenomas with malignant transformation have not been reported. In our case, the infiltration of the fibrous capsule by parenchymal cells may indicate malignant transformation...|$|E
40|$|Through allele-segregation and loss-of-heterozygosity analyses, we {{demonstrated}} {{loss of the}} translocation-derivative chromosome 3 in five independent renal cell tumors of the clear-cell type, {{obtained from}} three members of a family in which a constitutional t(2; 3) (q 35;q 21) was encountered. In addition, analysis of the <b>von</b> <b>Hippel-Lindau</b> <b>gene,</b> VHL, revealed distinct insertion, deletion, and substitution mutations {{in four of the}} five tumors tested. On the basis of these results, we conclude that, in this familial case, an alternative route for renal cell carcinoma development is implied. In contrast to the first hit in the generally accepted two-hit tumor-suppressor model proposed by Knudson, the familial translocation in this case may act as a primary oncogenic event leading to (nondisjunctional) loss of the der(3) chromosome harboring the VHL tumor-suppressor gene. The risk of developing renal cell cancer may be correlated directly with the extent of somatic (kidney) mosaicism resulting from this los...|$|E
40|$|The hypoxia-inducible factors (HIFs), HIF- 1 α and HIF- 2 α, are {{the central}} {{mediators}} of the homeostatic response that enables cells {{to survive and}} differentiate in low-oxygen conditions. Previous studies indicated that disruption of the <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> (Vhl) coincides with the activation of HIFα signaling. Here we show that inactivation of Vhl in mature osteoblasts/osteocytes induces their apoptosis and disrupts the cell/canalicular network. VHL-deficient (ΔVHL) mice exhibited a significantly increased cortical bone area resulting from enhanced proliferation and osteogenic differentiation of the bone marrow stromal cells (BMSCs) by inducing the expression of β-catenin in the BMSC. Our {{data suggest that the}} VHL/HIFα pathway in mature osteoblasts/osteocytes plays a critical role in the bone cell/canalicular network and that the changes of osteocyte morphology/function and cell/canalicular network may unleash the bone formation, The underlying mechanism of which was the accumulation of β-catenin in the osteoblasts/osteoprogenitors of the bone marrow...|$|E
40|$|AbstractInactivation of the <b>von</b> <b>Hippel-Lindau</b> (VHL) <b>gene</b> is {{associated}} with the development of highly vascularized tumors. pVHL targets the α subunits of hypoxia inducible factor (HIF) for ubiquitin-mediated degradation in an oxygen-dependent manner. Although pVHL-deficient tumor cell lines demonstrate constitutive stabilization and activation of HIF, it has yet to be shown that loss of murine Vhl alone is sufficient to dysregulate HIF. We utilized a genetic approach to demonstrate that loss of Vhl is sufficient not only to stabilize HIF-α subunits under normoxia, but also fully activate HIF-mediated responses. These studies have implications for the hierarchy of signaling events leading to HIF stabilization, nuclear translocation, and target gene expression. We further demonstrate that loss of murine Vhl does not promote teratocarcinoma growth, indicating that other genetic changes must occur to facilitate Vhl-mediated tumorigenesis...|$|R
40|$|SummaryThe <b>von</b> <b>Hippel-Lindau</b> tumor-suppressor <b>gene</b> (VHL) {{is lost in}} most {{clear cell}} renal cell carcinomas (ccRCC). Here, using human ccRCC specimens, VHL-deficient cells, and {{xenograft}} models, we show that miR- 204 is a VHL-regulated tumor suppressor acting by inhibiting macroautophagy, with MAP 1 LC 3 B (LC 3 B) as a direct and functional target. Of note, higher tumor grade of human ccRCC was correlated with a concomitant decrease in miR- 204 and increase in LC 3 B levels, indicating that LC 3 B-mediated macroautophagy is necessary for RCC progression. VHL, in addition to inducing endogenous miR- 204, triggered the expression of LC 3 C, an HIF-regulated LC 3 B paralog, that suppressed tumor growth. These data reveal a function of VHL as a tumor-suppressing regulator of autophagic programs...|$|R
50|$|The <b>von</b> <b>Hippel-Lindau</b> tumor {{suppressor}} <b>gene</b> {{generally has}} a germline mutation. This suppressor gene is also called elongin binding protein and G7 protein. The VHL protein {{is involved in}} up-regulation of hypoxic response via the hypoxia inducible factorHIF-1 alpha. Mutations generally prevent the production of any functional VHL protein or result in a change of structure of VHL protein. This genetic disorder shows an autosomal dominant inheritance pattern, with about 20% of patients possessing a new mutation. There are usually several other tumors which {{are part of the}} syndrome, including tumors of the central nervous system, kidneys, pancreas, adrenal glands, epididymis, broad ligament, along with the endolymphatic sac. The vast majority of patients with an endolymphatic sac tumor have <b>von</b> <b>Hippel-Lindau</b> syndrome.|$|R
40|$|Miniaturization is a {{hallmark}} of modern technologies. Notably, this feature has not spared molecular biology and its potential applications. Towards developing more effective therapeutics against cancer, studies began to explore {{more than a decade}} ago how natural tumor suppression could be translated into antineoplastic drugs. To this end, investigators focused on major constituents of a central pathway that protects cells against neoplastic transformation: the nuclear retinoblastoma protein (RB) pathway. As such, peptide mimetics of RB, p 16 and p 21 were developed. Likewise, the p 53 and <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> products which affect indirectly the RB pathway provided additional templates for the development of anti-proliferative peptides. Each of the peptides derived from these distinct tumor suppressors was made cell-permeable by its ligation to an amino acid sequence conferring cellular internalization. Details reviewed here reveal that through the application of such anti-cancer peptide therapeutics alone or in conjunction whenever synergy is to expect, the dark era of chemotherapy will likely be overcome, at last. Comment: 6 page...|$|E
40|$|The {{molecular}} {{mechanism of}} autocrine regulation of vascular endothelial growth factor (VEGF) in {{chronic lymphocytic leukemia}} (CLL) B cells is unknown. Here, we report that CLL B cells express constitutive levels of HIF- 1 alpha under normoxia. We have examined {{the status of the}} <b>von</b> <b>Hippel-Lindau</b> <b>gene</b> product (pVHL) that is responsible for HIF- 1 alpha degradation and found it to be at a notably low level in CLL B cells compared with normal B cells. We demonstrate that the microRNA, miR- 92 - 1, overexpressed in CLL B cells, can target the VHL transcript to repress its expression. We found that the stabilized HIF- 1 alpha can form an active complex with the transcriptional coactivator p 300 and phosphorylated-STAT 3 at the VEGF promoter and recruit RNA polymerase II. This is initial evidence that pVHL, without any genetic alteration, can be regulated by microRNA and explains the aberrant autocrine VEGF secretion in CLL. (Blood. 2009; 113 : 5568 - 5574...|$|E
40|$|International audienceHuman tumors {{exhibit a}} variety of genetic alterations, {{including}} point mutations, translocations, gene amplifications and deletions, as well as aneuploid chromosome numbers. For carcinomas, aneuploidy is associated with poor patient outcome for a large variety of tumor types, including breast, colon, and renal cell carcinoma. The Renal cell carcinoma (RCC) is a heterogeneous carcinoma consisting of different histologic types. The clear renal cell carcinoma (ccRCC) {{is the most common}} subtype and represents 85 % of the RCC. Central to the biology of the ccRCC is the loss of function of the <b>Von</b> <b>Hippel–Lindau</b> <b>gene,</b> but is also associated with genetic instability that could be caused by abrogation of the cell cycle mitotic spindle checkpoint and may involve the Aurora kinases, which regulate centrosome maturation. Aneuploidy can also result from the loss of cell–cell adhesion and apical–basal cell polarity that also may be regulated by the mitotic kinases (polo-like kinase 1, casein kinase 2, doublecortin-like kinase 1, and Aurora kinases). In this review, we describe the “non-mitotic” unconventional functions of these kinases in renal tumorigenesi...|$|E
40|$|AbstractRenal cell carcinomas (RCC), mostly {{occurring}} in adults aged 60 – 70  years, {{can result from}} well-known factors like cigarette smoking, obesity and hypertension. However, they {{have been associated with}} genetic alterations in children and young adults. A 28 year-old male patient with a confirmed RCC underwent biomolecular and immunohistochemical analyses due to his young age. A point mutation of the <b>von</b> <b>Hippel-Lindau</b> tumor suppressor <b>gene</b> was identified. Young patients under 40  years with diagnosed RCC should undergo additional diagnostic investigation, hence the discovery of an underlying cause. This could be important for further treatment and counseling of these young patients...|$|R
40|$|AbstractInactivation of the <b>von</b> <b>Hippel-Lindau</b> tumor {{suppressor}} <b>gene</b> {{is linked}} to the development of hereditary (VHL Disease-associated) and sporadic clear cell carcinoma of the kidney. The VHL gene product, pVHL, targets the heterodimeric transcription factor HIF for polyubiquitination, and restoration of pVHL function in VHL−/− renal carcinoma cells suppresses their ability to form tumors in nude mice. Here we show that tumor suppression by pVHL can be overridden by a HIF variant that escapes pVHL control. These studies prove that HIF is a critical downstream target of pVHL and establish that activation of HIF target genes can promote tumorigenesis in vivo...|$|R
40|$|Mutations in the <b>von</b> <b>Hippel-Lindau</b> (VHL) tumour-suppressor <b>gene</b> {{result in}} several forms of cancer. In the present study, we {{investigated}} {{the role of}} VHL subcellular localization in its antitumour properties. We generated renal cell carcinoma (RCC) lines stably expressing either exclusively nuclear (RCC/NLS-VHL), cytoplasmic (RCC/NES-VHL) or nucleo-cytoplasmic shuttling (RCC/NES-VHL or RCC/VHL) forms of VHL and investigated several parameters linked to tumorigenesis and known to be dysregulated in VHL disease. Remarkably, although the expression of wild-type VHL is largely cytoplasmic, all of the antitumour properties of VHL tested could be reconstituted by expressing exclusively nuclear VHL. Martin D Lewis and Ben J Robert...|$|R
